Australia’s Mesoblast says stem cell RA candidate aids post biologic therapy in PhII – FiercePharma
FiercePharma |
Australia's Mesoblast says stem cell RA candidate aids post biologic therapy in PhII
FiercePharma Melbourne-based biotech Mesoblast has updated on its rheumatoid arthritis stem–cell treatment MPC-300-IV, saying the candidate demonstrated dose-related safety and patient toleration improvements over a placebo in patients that failed to respond to … Mesoblast's Stem–Cell Treatment Shows Improvement In Rheumatoid Arthritis Patients Mesoblast seeks partner to develop rheumatoid arthritis stem cell treatment New stem–cell treatment shows promise for rheumatoid arthritis patients: report |
